Organogenesis Stock Forecast, Price & News

-0.24 (-1.43 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume5.48 million shs
Average Volume1.09 million shs
Market Capitalization$2.12 billion
P/E Ratio45.86
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ORGO News and Ratings via Email

Sign-up to receive the latest news and ratings for Organogenesis and its competitors with MarketBeat's FREE daily newsletter.

Organogenesis logo

About Organogenesis

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft, a dermal substitute for the treatment of DFUs; NuShield, a dehydrated placental tissue wound covering and surgical barrier applied to the target tissue to support native healing; and PuraPly Antimicrobial, an antimicrobial barrier skin substitute to treat chronic and acute wounds. Its surgical and sports medicine products comprise NuCel, a surgically implanted allograft used primarily in spinal and orthopedic surgical applications; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor, a chorionic membrane wound covering; TransCyte, a bioengineered tissue for the treatment of partial thickness burns; and Gintuit, a bioengineered bi-layered living cellular tissue for the treatment of mucogingival conditions in adults. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.38 out of 5 stars

Medical Sector

754th out of 2,100 stocks

Pharmaceutical Preparations Industry

375th out of 830 stocks

Analyst Opinion: 1.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Organogenesis (NASDAQ:ORGO) Frequently Asked Questions

Is Organogenesis a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Organogenesis stock.
View analyst ratings for Organogenesis
or view top-rated stocks.

What stocks does MarketBeat like better than Organogenesis?

Wall Street analysts have given Organogenesis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Organogenesis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Organogenesis?

Organogenesis saw a increase in short interest in May. As of May 28th, there was short interest totaling 3,320,000 shares, an increase of 32.8% from the May 13th total of 2,500,000 shares. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is presently 2.9 days. Approximately 5.3% of the company's stock are sold short.
View Organogenesis' Short Interest

When is Organogenesis' next earnings date?

Organogenesis is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Organogenesis

How were Organogenesis' earnings last quarter?

Organogenesis Holdings Inc. (NASDAQ:ORGO) posted its earnings results on Monday, May, 10th. The company reported $0.07 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.04) by $0.11. The company earned $102.55 million during the quarter, compared to analyst estimates of $86.30 million. Organogenesis had a net margin of 11.66% and a trailing twelve-month return on equity of 43.70%.
View Organogenesis' earnings history

How has Organogenesis' stock price been impacted by COVID-19 (Coronavirus)?

Organogenesis' stock was trading at $2.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ORGO shares have increased by 454.0% and is now trading at $16.51.
View which stocks have been most impacted by COVID-19

What guidance has Organogenesis issued on next quarter's earnings?

Organogenesis updated its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided EPS guidance of $- for the period. The company issued revenue guidance of $438 million-454 million, compared to the consensus revenue estimate of $397.24 million.

What price target have analysts set for ORGO?

4 equities research analysts have issued 1-year price targets for Organogenesis' stock. Their forecasts range from $9.00 to $26.00. On average, they expect Organogenesis' share price to reach $17.50 in the next year. This suggests a possible upside of 6.0% from the stock's current price.
View analysts' price targets for Organogenesis
or view top-rated stocks among Wall Street analysts.

Who are Organogenesis' key executives?

Organogenesis' management team includes the following people:
  • Mr. Gary S. Gillheeney Sr., Pres, CEO & Director (Age 66, Pay $1.58M)
  • Mr. Patrick Bilbo, Chief Operating Officer (Age 59, Pay $719.31k)
  • Mr. Brian Grow, Chief Commercial Officer (Age 45, Pay $675.22k)
  • Mr. David C. Francisco, Chief Financial Officer (Age 55)
  • Ms. Lori H. Freedman, VP & Gen. Counsel (Age 54)
  • Mr. Thomas L. Pearl, VP of HR
  • Dr. Zorina Pitkin, Sr. VP of Quality Systems
  • Mr. Henry Hagopian III, Sr. VP of Fin. & Treasurer (Age 53)
  • Mr. William R. Kolb CPA, Sec.

Who are some of Organogenesis' key competitors?

What other stocks do shareholders of Organogenesis own?

What is Organogenesis' stock symbol?

Organogenesis trades on the NASDAQ under the ticker symbol "ORGO."

Who are Organogenesis' major shareholders?

Organogenesis' stock is owned by a number of institutional and retail investors. Top institutional investors include Deerfield Management Company L.P. Series C (2.34%), BlackRock Inc. (1.79%), Pura Vida Investments LLC (1.18%), Emerald Mutual Fund Advisers Trust (1.10%), Nuveen Asset Management LLC (0.75%) and Assenagon Asset Management S.A. (0.71%). Company insiders that own Organogenesis stock include Alan A Ades, Albert Erani, Arthur S Leibowitz, Avista Capital Managing Member, Gary S Gillheeney, Glenn H Nussdorf, Michael W Katz, Starr Wisdom and Wayne D Mackie.
View institutional ownership trends for Organogenesis

Which institutional investors are selling Organogenesis stock?

ORGO stock was sold by a variety of institutional investors in the last quarter, including Prosight Management LP, Laurion Capital Management LP, Emerald Mutual Fund Advisers Trust, Morgan Stanley, Pura Vida Investments LLC, Walleye Capital LLC, Bank of Montreal Can, and Walleye Trading LLC. Company insiders that have sold Organogenesis company stock in the last year include Albert Erani, Gary S Gillheeney, Glenn H Nussdorf, and Starr Wisdom.
View insider buying and selling activity for Organogenesis
or view top insider-selling stocks.

Which institutional investors are buying Organogenesis stock?

ORGO stock was purchased by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, BlackRock Inc., Assenagon Asset Management S.A., Nuveen Asset Management LLC, Federated Hermes Inc., Prudential Financial Inc., EAM Investors LLC, and EAM Global Investors LLC. Company insiders that have bought Organogenesis stock in the last two years include Alan A Ades, Arthur S Leibowitz, Avista Capital Managing Member, Michael W Katz, and Wayne D Mackie.
View insider buying and selling activity for Organogenesis
or or view top insider-buying stocks.

How do I buy shares of Organogenesis?

Shares of ORGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Organogenesis' stock price today?

One share of ORGO stock can currently be purchased for approximately $16.51.

How much money does Organogenesis make?

Organogenesis has a market capitalization of $2.12 billion and generates $338.30 million in revenue each year. The company earns $17.95 million in net income (profit) each year or $0.16 on an earnings per share basis.

How many employees does Organogenesis have?

Organogenesis employs 910 workers across the globe.

What is Organogenesis' official website?

The official website for Organogenesis is

Where are Organogenesis' headquarters?

Organogenesis is headquartered at 85 Dan Road, Canton MA, 02021.

How can I contact Organogenesis?

Organogenesis' mailing address is 85 Dan Road, Canton MA, 02021. The company can be reached via phone at 781-575-0775 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.